



FOR IMMEDIATE RELEASE

Biosensors International Included in MSCI Small Cap Index; To Receive US \$5 Million Milestone Payment from Terumo

Singapore, 22 May 2007 - Biosensors International Group Ltd. (“Biosensors” or the “Company”, Bloomberg: BIG SP) today announced that it will be added to the MSCI Small Cap Index Series effective as of the market close of 31M ay 2007. MSCI is a leading provider of international equity indices which are widely accepted by institutional investors as performance bench marks in the selection and monitoring of investments.

Mr. Yoh Chie-Lu, Chairman and Chief Executive Officer of Biosensors commented; “We are pleased that we have been included in the MSCI Small Cap Index Series. This is a positive step for our investors and will further enhance Biosensors’ international profile”.

Additionally, Biosensors has been notified by its licensee, Terumo Corporation that the final milestone in the licensing agreement between the two firms has been achieved and the milestone payment of US\$5 million has been received by Biosensors.

Terumo’s in-license agreement with Biosensors relates to the Company’s proprietary Biolimus A9[®] drug and biodegradable polymer technologies used on its S-Stent[™] platform.

Mr. Lu said, “It is very encouraging to see the NOBORI program progressing through the regulatory process. Achievement of this final milestone is a giant step for Terumo towards the commercialization of the NOBORI drug-eluting stent in the Japanese market. We look forward to continued success in our alliance with Terumo.”

About MSCI Barra

MSCI Barra develops and maintains equity, fixed income, multi-asset class, REIT and hedge fund indices that serve as bench marks for an estimated USD 3 trillion on a worldwide basis. MSCI Barra’s risk models and analytics products help the world’s largest investors analyze, measure and manage portfolio and firm-wide investment risk. MSCI Barra is head quartered in New York, with research and commercial offices around the world. Morgan Stanley, a global financial services firm and a market leader in securities, asset management, and credit services, is the majority shareholder of MSCI Barra, and Capital Group International, Inc. is the minority shareholder. For additional information, please visit the website www.msclubarra.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary antirestenotic drug. It is pursuing three separate drug-eluting stent programs, BioMatrix®, Axxion™, and BioMatrix® Freedom™, a polymer-free drug-eluting stent. For additional information, please visit the website www.biosensors.com

Forward Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.

Media & Investor Relations Contacts

Singapore

Mr. Loh Chee Mun
Senior Vice President
Tel: (65) 621-35708
Email: cm.loh@biosensors.com

United States

Allen & Caron Inc.
Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949-474-4300
Email: matt@allencaron.com